Vineet Laboratories FY25 Loss Reaches ₹20.19 Crore

FY25 performance marks a sharp reversal

Vineet Laboratories Limited reported a substantial reversal in its financial performance for the year ended March 31, 2025. Revenue from operations fell to ₹75.00 crore in FY25 from ₹150.59 crore in FY24. The company consequently reported a loss after tax of ₹20.19 crore, compared with a profit after tax of ₹1.03 crore a year earlier. The figures were disclosed in the company’s Directors’ Report accompanying the audited financial statements. The change placed the company’s annual performance under closer scrutiny after FY24 had ended with a profit. Basic and diluted earnings per equity share also turned negative at ₹21.90 in FY25, against positive earnings of ₹1.11 in FY24.

Revenue declined by more than half

The decline in revenue was the central feature of Vineet Laboratories’ FY25 results. Total income stood at ₹75.00 crore, lower by ₹75.60 crore from the preceding year’s ₹150.59 crore. This represents a decline of about 50.2% year on year, based on the reported figures. A reduction of this scale can materially affect the ability of a manufacturing business to absorb fixed operating costs. The Directors’ Report identifies the reported income and profit figures but does not provide a detailed break-up of the causes behind the revenue decline in the supplied disclosure. Investors therefore need to distinguish between the reported financial outcome and explanations that have not been formally set out in the available material.

Profit moved from surplus to loss

The company’s profit after tax moved from ₹1.03 crore in FY24 to a loss of ₹20.19 crore in FY25. That is a negative swing of roughly ₹21.22 crore year on year. The loss per share of ₹21.90 reflected the impact on equity shareholders during the year. Both basic and diluted EPS were the same, at negative ₹21.90, compared with ₹1.11 in the prior year. This indicates that the reported loss was reflected consistently across the company’s stated per-share measures. The FY25 outcome was materially weaker than the prior year on both revenue and profitability.

Key financial figures

Note: Amounts reported in lakh rupees in the Directors’ Report have been converted to crore rupees. EPS remains in rupees per share.

FY26 results indicate a return to profit

Subsequent financial updates point to an improvement in reported profitability during FY26. Vineet Laboratories reported a FY26 net profit of ₹1.11 crore, reversing the FY25 loss of ₹20.19 crore. In the March 2026 quarter, the company reported a profit of ₹72.51 lakh, compared with a loss of ₹10.53 crore in the corresponding prior-year quarter. The FY26 annual EPS was reported at ₹1.00, compared with negative ₹21.90 in FY25. These figures indicate a return to annual profitability, although they do not by themselves establish a sustained growth trend.

Quarterly numbers remained uneven

The quarterly data supplied for FY26 shows varying revenue and profit trends. For the first quarter of 2026, Vineet Laboratories reported a loss per share of ₹0.94, improving from a loss per share of ₹2.31 in the first quarter of 2025. Revenue in that quarter was ₹7.46 crore, down 69% year on year, while net loss narrowed 59% to ₹86.6 lakh. In Q2 FY26, the company reported a net profit of ₹40 lakh, compared with a loss of ₹87 lakh in the immediately preceding quarter. Q2 revenue was ₹17.42 crore, down 8.12% year on year, while the reported operating margin improved to 18.25% from 4.30% in Q1 FY26. The quarterly data therefore shows improved margins and profitability in some periods alongside continuing pressure on sales.

What the annual turnaround means

The move back to a FY26 profit is relevant because it follows a large loss in FY25. The Q4 FY26 profit of ₹72.51 lakh accounted for a meaningful part of the reported annual profit of ₹1.11 crore. At the same time, revenue declines reported in the first two quarters of FY26 show that sales recovery was not uniform. For investors, the key distinction is between a recovery in profit and a broad-based recovery in revenue. The supplied information also notes negative return on equity and high debt levels among the company’s financial challenges, although no specific debt or return-on-equity figures are provided. Those factors may remain relevant when assessing the quality and durability of the reported turnaround.

Latest reported quarter and board meeting

The latest-quarter data in the supplied material states that revenue increased to ₹18.92 crore from ₹15.70 crore in the previous quarter. Net income moved from ₹85.1 lakh to ₹72.5 lakh over the same comparison, while the latest reported EPS was ₹0.43. Separately, Vineet Laboratories informed the BSE that its board meeting was scheduled for October 26, 2026, to consider and approve unaudited standalone financial results for the quarter ended June 30, 2026, along with the limited review report. The results and related review will provide the next formal update on the company’s operating and financial position.

Market relevance for shareholders

FY25 demonstrated the effect that a steep revenue contraction can have on annual profitability and shareholder earnings. FY26, in contrast, brought a return to profit and stronger reported operating margin in Q2, but quarterly sales data remained mixed. The company’s disclosures provide evidence of improvement in reported profits rather than confirmation of a complete revenue recovery. Shareholders will likely focus on whether future results can maintain positive earnings while improving sales levels. The October 2026 board consideration of the June-quarter results is the next identified event in the supplied disclosures.

Conclusion

Vineet Laboratories’ FY25 financials showed a steep decline in revenue and a ₹20.19 crore loss, compared with a modest profit in FY24. FY26 results subsequently showed a return to annual profitability, supported by a profitable March quarter and improved operating margin in Q2. However, reported quarterly revenue trends remained uneven. The company’s next unaudited quarterly results, scheduled for board consideration on October 26, 2026, will offer the next update on this recovery path.